Randomized Study of Albendazole in Patients With Epilepsy Due to Neurocysticercosis - Related Studies

Randomized Study of Albendazole in Patients With Epilepsy Due to Neurocysticercosis

This study is ongoing, but not recruiting participants.

Study NCT00004403. Last updated on June 23, 2005. Information provided by FDA Office of Orphan Products Development

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Epilepsy
		Cysticercosis

2	Additional conditions recognized in this trial
		Neurocysticercosis
		Taeniasis

3	More general conditions related to this trial
		Brain Diseases
		Central Nervous System Diseases
		Central Nervous System Helminthiasis
		Central Nervous System Infections
		Central Nervous System Parasitic Infections
		Cestode Infections
		Helminthiasis
		Nervous System Diseases
		Parasitic Diseases

4	Interventions listed in this trial
		albendazole
		dexamethasone
		phenytoin

5	More general drug interventions related to this trial
		Anthelmintics
		Anti-Infective Agents
		Anti-Inflammatory Agents
		Anticestodal Agents
		Antiemetics
		Antimitotic Agents
		Antineoplastic Agents
		Antineoplastic Agents, Hormonal
		Antiparasitic Agents
		Antiplatyhelmintic Agents
		Antiprotozoal Agents
		Autonomic Agents
		Central Nervous System Agents
		Gastrointestinal Agents
		Glucocorticoids
		Hormones
		Hormones, Hormone Substitutes, and Hormone Antagonists
		Mitosis Modulators
		Molecular Mechanisms of Pharmacological Action
		Peripheral Nervous System Agents
		Pharmacologic Actions
		Physiological Effects of Drugs
		Therapeutic Uses
		Tubulin Modulators

6	Sponsors listed in this trial
		FDA Office of Orphan Products Development
		Johns Hopkins University